Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 16/20 | 0.45 |
| ▸ | CCKAR | P32238 | 12/20 | 0.45 |
| ▸ | NOTCH1 | P46531 | 2/20 | 0.44 |
| ▸ | RBPJ | Q06330 | 2/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23013106 | 1.00 | CCKBR (0.45) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL23013247 | 0.96 | CCKBR (0.46) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL29692236 | 0.96 | CCKBR (0.46) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL29692144 | 0.95 | CCKBR (0.44) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL23023712 | 0.95 | CCKBR (0.44) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL23013405 | 0.95 | CCKBR (0.44) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL28749173 | 0.94 | CCKBR (0.45) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL29692141 | 0.94 | CCKBR (0.45) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL29939449 | 0.94 | CCKBR (0.46) | CCKBRCCKARNOTCH1RBPJBDKRB1 | |
| SCHEMBL29939406 | 0.94 | CCKBR (0.46) | CCKBRCCKARNOTCH1RBPJBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | claimed |
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-09-29 | — | — | US | disclosed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227507-B2 | Pharmaceutical compounds | CHRNA6, GABRA6, CHRNA7 | CCKBR 488/4885CCKAR 199/4885NOTCH1 4608/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | CCKBR 257/4885CCKAR 168/4885NOTCH1 4652/4885 |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | CHRNA6, GABRA6, CHRNA7 | CCKBR 488/4885CCKAR 199/4885NOTCH1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.